A startup backed by $80 million from investors is striking deals with a range of drug companies in its bid to lead the next wave of mental-health treatments.
Atai Life Sciences Is Assembling a Mental-Health Drug Platform
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced…
JOIN THE ATAI #INSIGHTNETWORK